Nanoviricides (NNVC) Cash from Investing Activities (2010 - 2025)
Nanoviricides (NNVC) posted Cash from Investing Activities of $1.0 for Q4 2025, up 100.0% sequentially from -$84317.0 in Q3 2025.
Nanoviricides (NNVC) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Nanoviricides has reported Cash from Investing Activities for 11 years, with the latest figure at $1.0 in Q4 2025.
- Quarterly Cash from Investing Activities changed N/A year-over-year to $1.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$94516.0 (up 34.78% YoY) and the FY2025 annual result came in at -$56964.0, up 63.62% from the prior year.
- Cash from Investing Activities rose to $1.0 in Q4 2025 per NNVC's latest filing, from -$84317.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $1.0 in Q4 2025 and troughed at -$110557.0 in Q1 2021.
- A 4-year average of -$41096.3 and a median of -$27416.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities tumbled 3725.53% in 2024, then surged 89.61% in 2025.
- Over 4 years, Cash from Investing Activities stood at -$110557.0 in 2021, then jumped by 95.05% to -$5474.0 in 2023, then sank by 754.29% to -$46764.0 in 2024, then jumped by 100.0% to $1.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $1.0, -$84317.0, and -$10200.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 |
| Dec 31, 2025 | 1.00 |
| Sep 30, 2025 | -84,317.00 |
| Sep 30, 2025 | -84,317.00 |
| Jun 30, 2025 | -10,200.00 |
| Jun 30, 2025 | -10,200.00 |
| Sep 30, 2024 | -46,764.00 |
| Sep 30, 2024 | -46,764.00 |
| Jun 30, 2024 | -98,163.00 |
| Jun 30, 2024 | -98,163.00 |
| Mar 31, 2024 | -44,632.00 |
| Mar 31, 2024 | -44,632.00 |
| Dec 31, 2023 | -5,474.00 |
| Dec 31, 2023 | -5,474.00 |
| Sep 30, 2023 | -8,291.00 |
| Sep 30, 2023 | -8,291.00 |
| Jun 30, 2023 | -2,566.00 |
| Jun 30, 2023 | -2,566.00 |
| Mar 31, 2021 | -110,557.00 |
| Mar 31, 2021 | -110,557.00 |